celecoxib has been researched along with Cancer of Kidney in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cytokine-naive metastatic renal cell carcinoma patients with tumors expressing ≥10% maximal COX-2 staining by immunohistochemistry received IFN-α 5 million units daily and celecoxib 400 mg orally twice daily in an open-label, single-arm phase II trial." | 2.76 | Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. ( Dreicer, R; Elson, P; Finke, JH; Garcia, JA; Ireland, J; Rini, BI; Schwandt, A; Triozzi, P; Wyckhouse, J; Zhou, M, 2011) |
| "The observed median time to disease progression (TTP) for the entire cohort was 3." | 2.72 | Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. ( Bok, R; Dunlap, S; Elchinoff, A; Rini, BI; Simko, J; Small, EJ; Weinberg, V; Yu, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, Q | 1 |
| Guo, J | 1 |
| Wang, G | 1 |
| Chu, Y | 1 |
| Hu, X | 1 |
| Schwandt, A | 1 |
| Garcia, JA | 1 |
| Elson, P | 1 |
| Wyckhouse, J | 1 |
| Finke, JH | 1 |
| Ireland, J | 1 |
| Triozzi, P | 1 |
| Zhou, M | 1 |
| Dreicer, R | 1 |
| Rini, BI | 2 |
| Onishi, T | 1 |
| Suzuki, H | 1 |
| Igarashi, T | 1 |
| Hu, XL | 1 |
| Zhao, LS | 1 |
| Liu, W | 1 |
| Shu, JB | 1 |
| Xu, L | 1 |
| Wang, ZF | 1 |
| Wang, X | 1 |
| Zhang, L | 1 |
| O'Neill, A | 1 |
| Bahamon, B | 1 |
| Alsop, DC | 1 |
| Mier, JW | 1 |
| Goldberg, SN | 1 |
| Signoretti, S | 1 |
| Atkins, MB | 1 |
| Wood, CG | 1 |
| Bhatt, RS | 1 |
| Weinberg, V | 1 |
| Dunlap, S | 1 |
| Elchinoff, A | 1 |
| Yu, N | 1 |
| Bok, R | 1 |
| Simko, J | 1 |
| Small, EJ | 1 |
| Krzyzanowska, MK | 1 |
| Tannock, IF | 1 |
| Lockwood, G | 1 |
| Knox, J | 1 |
| Moore, M | 1 |
| Bjarnason, GA | 1 |
3 trials available for celecoxib and Cancer of Kidney
| Article | Year |
|---|---|
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.
Topics: Adult; Aged; Carcinoma, Renal Cell; Celecoxib; Cyclooxygenase 2; Dendritic Cells; Dinoprostone; Drug | 2011 |
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carc | 2006 |
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.
Topics: Administration, Oral; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2007 |
4 other studies available for celecoxib and Cancer of Kidney
| Article | Year |
|---|---|
Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2017 |
[A case of favorable response after combination treatment with interferon-α and cyclooxygenase-2 inhibitor against metastatic renal cell carcinoma].
Topics: Aged; Carcinoma, Renal Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Huma | 2012 |
[Inhibitory effects of cyclooxygenase-2 selective inhibitor Celecoxib on human nephroblastoma].
Topics: Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; | 2012 |
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Celecoxib; Cell Line | 2013 |